Please visit our Pipeline page for Prothena's complete R&D Pipeline

✓

Pioneered fundamental discoveries elucidating the roles amyloid, γ-secretase and β-secretase play in AD1

✓

First to show that Aβ immunotherapy prevented and cleared amyloid plaques in the brains of transgenic mice2

✓

First to demonstrate plaque clearance by an N-terminus antibody in brains from patients with AD3

✓

Discovered fundamental contributions to understanding biology of ARIA  and vascular recovery following anti-Aβ immunotherapy4

We are developing numerous investigational drugs for Alzheimer’s and Parkinson’s diseases:

Investigational Drugs for Potential Treatment of Alzheimer’s Disease

PRX012: Subcutaneously Delivered Anti-Aβ mAb With Potent Binding
  • Investigational humanized mAb that has demonstrated potent binding to efficiently clear known pathogenic forms of Aβ, designed for improved patient access via SC delivery5
  • In Phase 1 clinical development (ASCENT Phase 1 clinical trial program)
  • Has been granted Fast Track designation by the FDA
BMS-986446 (PRX005): Anti-MTBR-Tau mAb
  • Targets the MTBR region of tau, which has the potential to reduce pathogenic tau spread
  • In Phase 1 clinical development under a Global Neuroscience Collaboration with Bristol Myers Squibb
PRX123: Investigational Dual Aβ/Tau Vaccine
  • Synergistic mechanism designed for increased efficacy over single-target vaccines for potential treatment and prevention of AD6
  • IND cleared by FDA

Investigational Drugs for Potential Treatment of Parkinson’s Disease

Prasinezumab: Anti-α-Synuclein mAb
  • Preferentially binds aggregated α-synuclein to reduce pathogenic spread and decrease synuclein pathology
  • Global collaboration with Roche. Phase 2 PASADENA trial and Phase 2b clinical trial PADOVA are ongoing
Aβ, amyloid beta; AD, Alzheimer’s disease; ARIA, amyloid-related imaging abnormalities; FDA, U.S. Food & Drug Administration; IND, Investigational New Drug Application; mAb, monoclonal antibody; MTBR, microtubule binding region; PD, Parkinson’s disease; R&D, research and development; SC, subcutaneous.
1. Games D, et al. Nature. 1995;373:523-527; 2. Schenk D, et al. Nature. 1999;400:173-177; 3. Rinne JO, et al. Lancet Neurol. 2010;9:363-372; 4. Zago W, et al. Alzheimers Dement. 2013;S105-S115; 5. Campbell B, et al. Presented at AD/PD™ 2023; March 28-April 1, 2023; Gothenburg, Sweden; 6. Barbour R, et al. Oral presentation at AD/PD™ 2022; March 15-20, 2022, Barcelona, Spain.